New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTOSIR, PSTI, ATHX, CUR, NBS, BCLIRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
05:09 EDTPSTIPluristem moves to large-scale manufacturing after second product line completed
Pluristem Therapeutics announced that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension. Pluristem's development plan for the PLX-RAD cells considers numerous potential clinical indications such as: enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency, which can result from immune system disorders, genetic diseases, and treatment of leukemia and other blood cancers; treatment of bone marrow deficiency in patients who have undergone chemotherapy; treatment of acute radiation syndrome, or ARS in conjunction with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases.
October 20, 2014
07:19 EDTPSTIIBC Life Sciences to hold a conference
Subscribe for More Information
October 17, 2014
08:05 EDTOSIROsiris, Arthrex announce exclusive commercial and development partnership
Subscribe for More Information
October 16, 2014
08:58 EDTBCLIBrainStorm CEO underappreciated by investors, Feuerstein says
BrainStorm CEO Tony Fiorino is "one of the most honest and diligent investors in the health care sector," TheStreet's Adam Feuerstein writes after interviewing the executive. Feuerstein believes Fiorino is being underappreciated by investors. Shares of the microcap company seeking to development a treatment for amyotrophic lateral sclerosis are up 20% to $4.15 in pre-open trading. Reference Link
October 14, 2014
16:42 EDTPSTIPluristem Therapeutics files $200M mixed securities shelf
06:05 EDTNBSBioLife Solutions biopreservation products used at Progenitor Cell Therapy
BioLife Solutions (BLFS) provided an update on use of the company's HypoThermosol storage/shipping media and CryoStor cryopreservation freeze media by Progenitor Cell Therapy, or PCT, a wholly owned subsidiary of NeoStem (NBS) a leader in the emerging cellular therapy field.
October 9, 2014
09:19 EDTCURNeuralstem treats first patient in Phase I spinal cord injury stem cell trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use